BEARINGPOINT
24.5.2023 08:55:27 CEST | Business Wire | Press release
Banks today need to continuously upgrade their digital products and services to meet customers’ evolving needs, especially regarding digital payments, and stand out in the fiercely competitive financial services sector.
In a recent client story, BearingPoint explains how it supported Hanseatic Bank in assessing its current IT architecture and then defining the requirements for an integration platform aligned with the bank’s business and IT strategies.
Reshaping the IT infrastructure into a flexible and scalable platform
With Hanseatic Bank, BearingPoint identified various use cases for a minimum viable product (MVP), starting from system integration pain points. A series of workshops held with key stakeholders resulted in developing, implementing, and operating an event-driven integration solution for a payment use case in the cloud that can transform, orchestrate, and process data.
Building on an AWS infrastructure, BearingPoint combined Apache Kafka, an open-source distributed event-streaming platform, and Camunda, a process orchestration platform that designs, orchestrates and improves business processes. The new integration platform including necessary governance is now available to several teams for developing and taking further use cases to production one by one as they arise. Consequently, the future operating model has been redesigned and now focuses on a more decentralized and micro-service approach to bring products and services to market faster, in an iterative way.
“Payment transactions are undergoing major changes. This innovative IT move turned thought leadership into reality in this project. A best-practice approach for modern architecture and efficiency in payments,” said Christian Bruck, Partner at BearingPoint.
Enabling agile ways for building digital service offerings faster
Hanseatic Bank is well-positioned for the future with a modern, scalable, and flexible IT architecture. The bank can now react more quickly to the changing market demands and develop new products and services effectively and efficiently.
Hanseatic Bank has already brought to life an improved digital service that helps customers to select and adjust repayment rates for open credit card transactions. By changing the existing process from an semi-automated processes with human interactions into a reusable real-time process leads to a higher customer satisfaction due to direct response via the banking app or online banking instead of a 24h wait. Further services from different teams are already in the pipeline of the new integration platform.
“The combination of different areas of expertise and team collaboration were key to success. From solution design and business processes to governance and development, BearingPoint delivered with us a successful MVP go-live with a hands-on team,” said Nico Koller, IT Project Lead at Hanseatic Bank.
About Hanseatic Bank
Hanseatic Bank has been at home in Hamburg since it was founded in 1969, but from the outset it has operated with customers and partners throughout Germany. Werner Otto had founded the consumer credit institution to enable customers of Otto Versand to finance their purchases. In 2005, the major French bank Société Générale took over 75 percent of the shares, while the Otto Group continues to hold 25 percent. In the meantime, both the customer base and the product range have expanded significantly. The bank’s business areas now also include deposit business, insurance, receivables management and consumer loans. One specialty is its credit cards with innovative services for customers and cooperation partners. Further information: https://www.hanseaticbank.de.
About BearingPoint
BearingPoint is an independent management and technology consultancy with European roots and a global reach. The company operates in three business units: Consulting, Products, and Capital. Consulting covers the advisory business with a clear focus on selected business areas. Products provides IP-driven digital assets and managed services for business-critical processes. Capital delivers M&A and transaction services.
BearingPoint’s clients include many of the world’s leading companies and organizations. The firm has a global consulting network with more than 10,000 people and supports clients in over 70 countries, engaging with them to achieve measurable and sustainable success.
For more information, please visit:
Homepage: www.bearingpoint.com
LinkedIn: www.linkedin.com/company/bearingpoint
Twitter: @BearingPoint
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230523005700/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
